Payment overview · 2025
General Payments
$994.11
60 reported records · 20 companies
Healthcare provider profile · identity verified
Leslie Ann Murphy, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · NORTON, OH · NPI 1881677813
Verified facts
What the public records show
CMS Open Payments records show Leslie Ann Murphy, M.D. received $994.11 in general payments during 2025 across 60 reported records.
ABBVIE INC. accounted for 23.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $231.35 | 23.3% | 20 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $119.93 | 12.1% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $76.60 | 7.7% | 3 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $60.94 | 6.1% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $60.89 | 6.1% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $50.64 | 5.1% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $49.19 | 5.0% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $41.37 | 4.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $33.91 | 3.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.68 | 3.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.39 | 3.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.16 | 3.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $28.39 | 2.9% | 1 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $26.15 | 2.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.30 | 2.3% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $20.22 | 2.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.99 | 2.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.91 | 2.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.85 | 1.9% | 1 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $14.25 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $994.11 | 60 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $141.96 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $141.96 | 11 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $89.39 | 9 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $82.04 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $76.60 | 3 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $60.94 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $60.89 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $50.64 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $49.19 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $41.37 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.89 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $33.91 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.39 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.39 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.16 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $31.16 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $28.39 | 1 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $26.15 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $23.30 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| Xtandi Normalized: xtandi |
Drug | Astellas Pharma US Inc | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $14.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 64 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
53 | 15 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
64 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
86 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 554 | 176 |
| Lisinopril | Lisinopril | 434 | 128 |
| Levothyroxine Sodium | Levothyroxine Sodium | 368 | 112 |
| Amlodipine Besylate | Amlodipine Besylate | 332 | 114 |
| Omeprazole | Omeprazole | 311 | 97 |
| Losartan Potassium | Losartan Potassium | 258 | 83 |
| Hydrochlorothiazide | Hydrochlorothiazide | 235 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 228 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 205 | 77 |
| Metformin Hcl | Metformin Hcl | 152 | 44 |
| Simvastatin | Simvastatin | 144 | 49 |
| Citalopram Hbr | Citalopram Hydrobromide | 140 | 38 |
| Metformin Hcl Er | Metformin Hcl | 115 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 115 | 39 |
| Gabapentin | Gabapentin | 109 | 53 |
| Carvedilol | Carvedilol | 108 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 36 |
| Sertraline Hcl | Sertraline Hcl | 102 | 40 |
| Trazodone Hcl | Trazodone Hcl | 100 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 96 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 96 | 33 |
| Meloxicam | Meloxicam | 94 | 34 |
| Eliquis | Apixaban | 86 | 27 |
| Tramadol Hcl | Tramadol Hcl | 86 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 82 | 33 |
| Buspirone Hcl | Buspirone Hcl | 80 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 27 |
| Potassium Chloride | Potassium Chloride | 78 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 77 | 69 |
| Montelukast Sodium | Montelukast Sodium | 77 | 25 |
| Furosemide | Furosemide | 75 | 30 |
| Prednisone | Prednisone | 71 | 53 |
| Ozempic | Semaglutide | 64 | 23 |
| Methylprednisolone | Methylprednisolone | 61 | 59 |
| Lorazepam | Lorazepam | 59 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 16 |
| Allopurinol | Allopurinol | 56 | 15 |
| Glimepiride | Glimepiride | 56 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 23 |
| Famotidine | Famotidine | 53 | 21 |
| Jardiance | Empagliflozin | 53 | 18 |
| Synthroid | Levothyroxine Sodium | 53 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 16 |
| Ezetimibe | Ezetimibe | 49 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 17 |
| Alendronate Sodium | Alendronate Sodium | 40 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 19 |
| Ibuprofen | Ibuprofen | 33 | 19 |
| Pregabalin | Pregabalin | 33 | 14 |
| Spironolactone | Spironolactone | 31 | 12 |
| Valsartan | Valsartan | 29 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Cephalexin | Cephalexin | 24 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | 13 |
| Glipizide Er | Glipizide | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | 14 |
| Valacyclovir | Valacyclovir Hcl | 23 | 12 |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 17 |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 17 |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Nystatin | Nystatin | 17 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 17 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 17 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Prolia | Denosumab | 13 | 11 |
| Temazepam | Temazepam | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $994.11 · 60 records | ABBVIE INC. | AUSTEDO XR, Auvelity, CAPVAXIVE, Cologuard Collection Kit, GARDASIL 9, GEMTESA, INJECTAFER, KEVEYIS, LEQVIO, Leqembi, MOUNJARO, NEXLETOL, NURTEC ODT, Ozempic, QULIPTA, ROTATEQ, Rybelsus, TRINTELLIX, TRUDHESA, UBRELVY, VAXELIS, VAXNEUVANCE, VRAYLAR, Wegovy, XIFAXAN, Xelstrym, Xtandi, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error